We are testing a new drug, LY3537982, in patients with advanced solid tumors that have a specific genetic mutation. The goal is to see how well it works and how safe it is when used alone or with other cancer treatments.
Health conditions and diseases that the clinical trial is designed to study and treat.
KRAS G12C-Mutant Advanced Solid Tumors are a type of cancer that occurs when there is a specific mutation in the KRAS gene, leading to uncontrolled cell growth. This mutation is often found in various solid tumors, including lung and colorectal cancers.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.